Explore
Validate
Learn
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Immunocytochemistry [1]
- Immunohistochemistry [1]
- Other assay [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-81879 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- MLLT11 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- Immunogen sequence: FWRMPIPELD LSELEGLGLS DTATYKVKDS SVGKMIGQAT AADQEKNPEG DGLLEYSTFN FWRAPIASIH SFEL
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 0.2 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references MLLT11-TRIL complex promotes the progression of endometrial cancer through PI3K/AKT/mTOR signaling pathway.
Liao J, Chen H, Qi M, Wang J, Wang M
Cancer biology & therapy 2022 Dec 31;23(1):211-224
Cancer biology & therapy 2022 Dec 31;23(1):211-224
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of MLLT11 in SH-SY5Y cells using a MLLT11 polyclonal antibody (Product # PA5-81879). The analysis shows localization to nucleoplasm & cytosol.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of MLLT11 in human cerebral cortex using a MLLT11 polyclonal antibody (Product # PA5-81879). The analysis shows moderate cytoplasmic and nuclear positivity in neuronal cells.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4. Effects of MLLT11 and TRIL on tumor phenotype. Western blot was performed to verify the effect of siRNA inhibition on the intracellular expression of (a) MLLT11 and (b) TRIL. (c) Suppression of MLLT11 and TRIL at the RNA level by siRNA was determined by qPCR. *** p < .001. Wound scratch healing assay was performed to detect the alteration of migration ability of (d) ECC-1 and (e) Ishikawa cells after MLLT11 and TRIL inhibition by siRNA. *** p < .001. (f) Flow cytometry was used to detect the effect of apoptosis rate after inhibition of MLLT11, TRIL, and combined inhibition of MLLT11 and TRIL by siRNA, respectively, in ECC-1 and Ishikawa cells. (g) The photo of nude mice tumor tissues in the lentivirus knockdown MLLT11, TRIL and MLLT11-TRIL co-knockdown groups (Lv/sh-MLLT11, Lv/sh-TRIL and Lv/sh-M + T) and its control group (Lv/sh-scramble). (h) Line graphs of tumor size of nude mice in the MLLT11, TRIL, MLLT11-TRIL co-knockdown and Lv/sh-scramble groups at different time points.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5. Interaction between the MLLT11-TRIL and PI3K/AKT/mTOR signaling pathway. Western blot was used to detect the effects of LY294002, MK-2206 and Rapamycin on the protein expression of MLLT11 and TRIL in cells. (b) Western blot was used to detect the effects of 740Y-P and IGF-1 on the protein expression of MLLT11 and TRIL in cells. (c) Isolation of nuclear and cytoplasmic proteins to examine the effects of LY294002 and IGF-1 on the subcellular distribution of MLLT11 and TRIL. Co-IP detected the interaction between cell endogenous protein MLLT11 and TRIL. The immunoprecipitates were immunoblotted (IB) with TRIL (d) or MLLT11 (e) antibody.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 6. Co-IP detected the interaction between MLLT11-TRIL and AKT. The cell lysate was immunoprecipitated with IgG, MLLT11 (a) or TRIL (b) antibody. And immunoprecipitates were immunoblotted (IB) with pan-AKT antibody. After IGF-1 treated the cells, the above experiment was repeated. The immunoprecipitates were immunoblotted with pan-AKT antibody. The control group was treated with DMSO.
